Fulcrum Therapeutics Inc. (FULC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised cancer-risk concerns, which left no viable regulatory path for the treatment.
After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call Transcript
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion
Fulcrum Therapeutics (FULC) pivots to pociredir for severe sickle cell disease after discontinuing losmapimod. Pociredir's Phase 1 PIONEER data shows 7/12 patients hitting the ≥20% HbF threshold, but mean HbF just misses the mark. FULC's valuation is tied almost entirely to pociredir, with a risk-adjusted NPV of $136 million and $352.3 million in cash.
Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
The consensus price target hints at a 75.7% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript
Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript
Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
Fulcrum Therapeutics (FULC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
